Corporate Profile

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases.
Featured Documents
3/2/20
March 2020 Corporate Presentation

Share Price

Price
Change (%)  (%)
Volume
Data as of

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events
There are currently no events scheduled.
Recent News
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany
4/7/20
SAN DIEGO , April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing
Read More →
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
4/6/20
SAN DIEGO , April 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing
Read More →
La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany
4/3/20
SAN DIEGO , April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing
Read More →